In vivo pharmacology of the dopaminergic stabilizer pridopidine (Q34128435)

31 July 2017

In vivo pharmacology of the dopaminergic stabilizer pridopidine (English)

1 reference

Dopamine D2 Receptor Antagonists

31 July 2017

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20667452

12 June 2024

6

Clas Sonesson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20667452

12 June 2024

author name string

Henrik Ponten

1

1 reference

31 July 2017

Johan Kullingsjö

2

1 reference

31 July 2017

Sören Lagerkvist

3

1 reference

31 July 2017

Peter Martin

4

1 reference

31 July 2017

Fredrik Pettersson

5

1 reference

31 July 2017

Susanna Waters

7

1 reference

31 July 2017

Nicholas Waters

8

1 reference

31 July 2017

language of work or name

English

0 references

publication date

24 July 2010

1 reference

full work available at URL

31 July 2017

https://doi.org/10.1016/j.ejphar.2010.07.023

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20667452

https://api.elsevier.com/content/article/PII:S001429991000720X?httpAccept=text/xml

12 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

https://api.elsevier.com/content/article/PII:S001429991000720X?httpAccept=text/plain

12 June 2024

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

European Journal of Pharmacology

12 June 2024

published in

1 reference

31 July 2017

644

1 reference

31 July 2017

1-3

1 reference

31 July 2017

88-95

1 reference

Parallel Organization of Functionally Segregated Circuits Linking Basal Ganglia and Cortex

31 July 2017

1

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

Olanzapine/fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder

12 June 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties

12 June 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

Dopamine and noradrenaline efflux in the prefrontal cortex in the light and dark period: effects of novelty and handling and comparison to the nucleus accumbens.

12 June 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

Advances in the Pharmacological Management of Huntingtonʼs Disease

12 June 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

The functional state of the dopamine receptor in the anterior pituitary is in the high affinity form.

12 June 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade.

12 June 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist

12 June 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

Glutamate receptors as therapeutic targets for Parkinson's disease

12 June 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function

12 June 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia

12 June 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function

12 June 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum.

12 June 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications.

12 June 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

Combined alpha2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat.

12 June 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission

12 June 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study

12 June 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone

12 June 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for mot

12 June 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

The other face of depression, reduced positive affect: the role of catecholamines in causation and cure

12 June 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

Synthesis and evaluation of a set of 4-phenylpiperidines and 4-phenylpiperazines as D2 receptor ligands and the discovery of the dopaminergic stabilizer 4-[3-(methylsulfonyl)phenyl]-1-propylpiperidine (huntexil, pridopidine, ACR16).

12 June 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

Behavioral and neurochemical repercussions of hippocampal network activity blockade during the neonatal period

12 June 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders

12 June 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

The dopaminergic stabilizers (-)-OSU6162 and ACR16 reverse (+)-MK-801-induced social withdrawal in rats

12 June 2024

Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization

29

0 references

30

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

Dopamine displaces [3H]domperidone from high-affinity sites of the dopamine D2 receptor, but not [3H]raclopride or [3H]spiperone in isotonic medium: Implications for human positron emission tomography

12 June 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

The dopaminergic stabilizer ASP2314/ACR16 selectively interacts with D2(High) receptors.

12 June 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain

12 June 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

Antipsychotic drug action: antagonism, inverse agonism or partial agonism

12 June 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912.

12 June 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update

12 June 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

The dopamine D3 receptor and autoreceptor preferring antagonists (+)-AJ76 and (+)-UH232; a microdialysis study

12 June 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain.

12 June 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum

12 June 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

Comparison of effects of drugs on dopamine metabolism in the substantia nigra and the corpus striatum of rat brain.

12 June 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.EJPHAR.2010.07.023

12 June 2024

Identifiers

1 reference

31 July 2017

1 reference